GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » Quality Rank

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Quality Rank


View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Harbin Gloria Pharmaceuticals Co Quality Rank Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Executives
Guo Yun Pei Independent director
Wang Yu Supervisors
Yang Hong Bing Director
Diao Xiu Qiang Directors, executives
Liu Yue Yin Securities Affairs Representative
Guo Lei Feng Directors, Directors, and Executives
Li Jun Ling Director
Yang Hai Feng Executives
Zhang Su Mei Supervisors
Zhu Ji Man Director